Gemina Laboratories to Participate in Poster Session at American Association of Clinical Chemistry Annual Scientific Meeting

Gemina to present achievement of another significant technical milestone.

VANCOUVER, BC / ACCESSWIRE / June 15, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7), a specialist in fast, affordable, and accurate diagnostic tests, is pleased to announce the company's attendance at the American Association of Clinical Chemistry ("AACC") Annual Scientific Meeting & Clinical Lab Expo running from Sunday, July 23rd, 2023 to Thursday, July 27th, 2023 in Anaheim, California.

Gemina will be participating in the AACC poster session running from 9:30 am to 5:00 pm on Tuesday, July 25^th and Wednesday, July 26^th, during which we will announce another major milestone achieved with the Gemina Bridge protein immobilization chemistry on the lateral flow assay format.

Attendees at the conference who wish to speak with the Gemina team in person, should come to the Gemina poster between 1:30 pm and 2:30 pm on the Tuesday and Wednesday. The e-poster and audio narration will also be available online through the AACC Digital Platform from Tuesday, July 25^th for Digital Pass Select attendees and from Friday, July 28^th for in-person attendees.

In parallel with the poster presentation the poster will also be available on the Gemina Website for non attendees of AACC.

On Behalf of the Board of Directors

Brian Firth
CEO

Gemina Laboratories Ltd.

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

For more information regrading the Company, please contact:

Gemina Laboratories Ltd

Brian Firth, Chief Executive Officer
Email: investor@geminalabs.com

SOURCE: Gemina Laboratories Ltd.